SPARC

Peer Group

Stock Name
Peer Group Rank
RS Rating
1 Month RS
3 Month RS
Listing Date
Basic Industry
Market Cap
1 Day Returns(%)
1 Week Returns(%)
1 Month Returns(%)
3 Month Returns(%)
6 Month Returns(%)
1 Year Returns(%)
% from 52W High
% from 52W Low
Chart Type
Stock Price
200 Days MA
150 Days MA
50 Days MA
20 Days MA
200 Days EMA
50 Days EMA
21 Days EMA
20 Days EMA
10 Days EMA
30 Days Average Price * Volume
1 Month High
3 Month High
Float Shares
Index
52 Week High
Volume Spike
Gap Up
Dense Volume
Sector
Free Float(%)
Is HVE
HVE Date
Is Positive Volume HVE
Is HVY
HVY Date
Is Positive Volume HVY
Is HVQ
HVQ Date
Is Positive Volume HVQ
Day Range(%)
Is F&O Stock
Circuit Limit
RVOL
Daily Price Turnover 20
Daily Price Turnover 50
Daily Price Turnover 100
Is NR7
20 Days MA Volume
50 Days MA Volume
200 Days EMA Volume
50 Days EMA Volume
20 Days EMA Volume
Trend Reversal
% from 52W High 200 Days EMA Volume
200 Days EMA RS
50 Days EMA RS
20 Days EMA RS
% from 52W High RS
5 Days MA ADR(%)
14 Days MA ADR(%)
20 Days MA ADR(%)
30 Days MA ADR(%)
% Days in 125: EMA50 today > yesterday
% Days in 125: Today's price > EMA50
% from ATH
Quarterly Results Date
Gap Up %
MA Uptrend
FVG
Backtesting Closing Data
Highest Close Since Last Quarter
Past Result Dates
Company Name
Returns since Earnings(%)
Max Returns since Earnings(%)
Latest Investor Presentation Link
3 Day Range(%)
5 Day Range(%)
7 Day Range(%)
20 Day Range(%)
Exchange
Horizontal Resistance Line Data
Tight Zone Data
Inside Bar Dates
VCP Drawings Data
Industry 1D Performance Rank
Industry 1W Rank
Industry 1M Rank
Industry 3M Rank
Net Profit Latest Quarter
Net Profit Previous Quarter
Net Profit 2 Quarters Back
Net Profit 3 Quarters Back
Net Profit Last Year Quarter
Net Profit 5 Quarters Back
Net Profit 6 Quarters Back
Net Profit 7 Quarters Back
QoQ % Net Profit Latest
YoY % Net Profit Latest
EPS Latest Quarter
EPS Previous Quarter
EPS 2 Quarters Back
EPS 3 Quarters Back
EPS Last Year Quarter
EPS 5 Quarters Back
EPS 6 Quarters Back
EPS 7 Quarters Back
QoQ % EPS Latest
YoY % EPS Latest
EPS Last Year
EPS 2 Years Back
Sales Latest Quarter
Sales Previous Quarter
Sales 2 Quarters Back
Sales 3 Quarters Back
Sales Last Year Quarter
Sales 5 Quarters Back
Sales 6 Quarters Back
Sales 7 Quarters Back
QoQ % Sales Latest
YoY % Sales Latest
Sales Growth 5 Years(%)
OPM Latest Quarter
OPM Previous Quarter
OPM 2 Quarters Back
OPM 3 Quarters Back
OPM Last Year Quarter
OPM 5 Quarters Back
OPM 6 Quarters Back
OPM 7 Quarters Back
QoQ % OPM Latest
YoY % OPM Latest
Latest Quarter
ROE(%)
ROCE(%)
D/E
OPM TTM(%)
P/E
FII % change QoQ
DII % change QoQ
Promoter % change QoQ
PEG
Forward P/E
Historical P/E 5 Years
Company Info
Promotor Holding Latest Quarter(%)
Public Holding Latest Quarter(%)
FII Holding Latest Quarter(%)
DII Holding Latest Quarter(%)
Promotor Holding Previous Quarter(%)
FII Holding Previous Quarter(%)
DII Holding Previous Quarter(%)
Price to Book
Enterprise Value
Enterprise Value/EBITDA
Enterprise Value/Sales
286879014/01/2003Biotechnology5399-1.218.916.923.125.11218.654.1DAILY166.43137134.53134.67150.27141.64141.11150.3150.86158.0956.4FalseFalse11.14NAFalseFalseFalse144.2Healthcare34.3FalseFalseFalseFalseTrue06/05/2026True6.2False200.7473.553.137False3621694.62601439.62460074.363213171.314439653.94False20.473.5683.0484.35085.85.36.237.637.67218/05/2026-0.9False,True;False,False;False,False[False, False, False]['2025-06-02', 204.4, '2026-03-23', 108.0]173.09Dec 2025:09/02/2026,Sep 2025:10/11/2025,Jun 2025:04/08/2025Sun Pharma Advanced Research Company Limited20.632.3Jun 2025:NA,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/3e382a0b-33a2-48ff-8bfa-b1d6fc022ec7.pdf11.323.523.925.1NSE['WEEKLY', '2026-05-11', '2026-05-04']451242-80.57-75.97-52.03-60.98-79.71-107.69-96.84-106.69-6.1-1.1-2.48-2.34-1.6-1.88-2.46-3.32-2.98-3.29-6-0.8-10.64-11.968.457.869.6427.1914.9112.8616.8116.567.5-43.3-1.35-673.02-838.3-542.84-198.31-498.86-807.54-565.85-649.2819.7-34.9Dec 2025NA-297.83NA-430.96
-20
00.10NA-16.78NASun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India. **Website:** [https://www.sparc.life](https://www.sparc.life)65.6731.412.040.8865.672.040.78NA5817.44-26.45109.47
186938901/08/2016Biotechnology4141-5.33.423.620.811.824.711.746.8DAILY369.8310.54304.36303.56332.96310.78315.83337.51338.9356.7927FalseFalse6.36NAFalseFalseFalse118.9Healthcare56.7FalseFalseFalseFalseTrue11/05/2026True6.1False200.8524.712.99False738698.05384891.7349308.42563634.641010141.5False3379.5785.2286.522.35.44.53.94.137.637.635.209/05/20260.1False,False;False,False;False,False[False, True, False]['2026-05-11', 419.0, '2026-03-30', 251.9]359.85Dec 2025:31/01/2026,Sep 2025:12/11/2025,Jun 2025:02/08/2025Advanced Enzyme Technologies Limited3.517.3Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6926ddae-87f0-461d-84f9-b39a39161b6d.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cddf073-491e-4bdf-907a-5c5e21684dee.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/5c354304-ec2f-4ebe-82ed-74a8a9f086c1.pdf,Mar 2026:https://www.bseindia.com/xml-data/corpfiling/AttachLive/0276b659-a9b1-4b22-8c8b-e6abf442e7e4.pdf15.716.117.129.6NSE45124245.2543.1844.7440.4426.7338.8833.3934.974.869.33.843.83.873.572.373.372.943.051.16215.0711.72203.37171.95184.53185.91167.18169.11146.1154.5218.321.68.2431.0928.732.5530.3527.2832.6729.0333.128.314Mar 202610.5113.890.0230.72
24.5
-0.35-0.10.221.8724.0828.62Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India. **Website:** [https://www.advancedenzymes.com](https://www.advancedenzymes.com)43.2625.8525.55.4143.0425.855.512.544056.9615.375.44
378877207/04/2004Biotechnology652253.19.316.77.3-0.822.65.326.6DAILY402.45373.97376.81370.66365.84369.89369.91371.08371.43378.93145.7TrueTrue89.28Nifty Pharma,Nifty Healthcare,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400FalseFalseFalse110.3Healthcare55.1FalseFalseFalseFalseFalseFalse3.5TrueNo Band2.89130.1133.5115.7False3881049.853984852.63738670.764166401.645081824.56False17.977.8576.5676.534.942.82.52.850.450.417.507/05/20260.6False,False;False,False;False,False[False, False, False]['2025-11-18', 425.0, '2025-05-12', 317.9]395.85Dec 2025:12/02/2026,Sep 2025:11/11/2025,Jun 2025:07/08/2025Biocon Limited5.36.4Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d463313-de41-416f-8dc6-428934f9a499.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a2a272c9-3495-4e33-81c5-a3d9ec77cfc2.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/da900c6c-2204-4fe1-9b32-e56558e00b7f.pdf,Mar 2026:https://www.bseindia.com/xml-data/corpfiling/AttachLive/3cd77dab-72a2-4ccd-b4c1-ebcc8bb63d60.pdf8.68.711.714.7NSE[404.5, '24/12/2025', 'DAILY'][404.5, '01/12/2025', 'WEEKLY'][404.5, '01/06/2021', 'MONTHLY']451242198.6-51.8132.889.2459.481.127.1861.8483.4-56.80.781.080.630.232.870.21-0.135.49-27.8-72.82.388.444516.641734295.53941.944173821.43590.43432.98.22.318.8322.5919.9719.451924.4119.6719.0918.0713.1-7.5Mar 20261.43.750.4520.41
169.1
0.132.34-9.54-11.37128.9948.73Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. **Website:** [https://www.biocon.com](https://www.biocon.com)44.9123.47.5224.0154.457.3921.671.9277473.9320.44.58
435242530/06/2017Biotechnology18821-1.4-0.1-2.3-10.1-13.8-3.428.913.1DAILY1357.61534.961470.691351.981379.761454.331371.371365.071365.251366.7719.1FalseFalse6.39Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400FalseFalseFalse69.6Healthcare46.1FalseFalseFalseFalseTrue21/04/2026False2.5False200.331397.5False137847.595660.08124186.62102296.1899974.71False49.451.5739.9637.1654.52.33.53.73.913.613.628.9NA0False,False;False,False;False,False[False, False, False]['2025-06-12', 1910.0, '2026-04-28', 1200.0]1465.5Dec 2025:13/02/2026,Sep 2025:12/11/2025,Jun 2025:05/08/2025Eris Lifesciences Limited-46.8Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43898fb3-5cce-4a07-a7c3-23a5d48ec076.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf3953dd-4192-4e75-bb18-ef12c6218972.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/72b59bc9-f080-4758-a1b5-011cba783b2f.pdf4.94.96.818.8NSE451242108.83134.47125.1102.3587.0696.3589.5579.7-19.1257.328.828.666.896.156.736.125.22-171925.8428.82807.45792.41773705.3727.45741.17719.72550.931.91121.9234.8836.3735.835.7834.4135.6934.7326.94-4.11.4Dec 202512.8812.220.7735.7
42.8
-0.460.04-0.93-8.5946.3730.19Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti53.9219.336.3920.3554.856.8520.315.9821130.9818.976.86
517663018/08/2023Biotechnology11791-6-4.97.7-8.3-23-25.447.614.2DAILY1127.21386.261283.071114.511111.871338.041131.981130.181131.751157.2935.7FalseFalse5.85Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400FalseFalseFalse117.2Healthcare55.9FalseFalseFalseFalseFalseFalse7.3False200.6245.882.455False322638.8576082.94326930.64355537.89286594.32False39.815.4514.4316.04324.64.54.24.18857.7NA0.2False,False;False,False;False,False[False, True, False]['2025-06-11', 2150.4, '2026-04-02', 987.0]1251.6Dec 2025:11/02/2026,Sep 2025:13/11/2025,Jun 2025:08/08/2025Concord Biotech Limited-9.43.7Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f54b2085-70a6-491f-b5ce-a4d920857a6d.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f934c394-3b55-470f-b81b-acb031601389.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/6975260d-17bd-413a-a9cc-0f04f2b97a69.pdf8.19.69.618.1NSE45124267.7862.942.57141.9474.0998.759.5995.027.8-8.56.486.014.0713.427.089.435.79.087.8-8.535.6529.13278.13247.06203.99429.88244.22310.18215.8318.9712.613.918.5636.7636.6530.144.340.1144.0637.6641.410.3-8.4Dec 202521.3528.35038.36
37.4
0.21-0.3601.3843.4951.64Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India. **Website:** [https://www.concordbiotech.com](https://www.concordbiotech.com)44.0838.97.799.2244.087.589.586.4611777.2223.9810.16
6592015/11/2021Biotechnology811-4.95.5-6.8-12.2-41.9-50.564.626.6DAILY21.0830.0228.0220.2821.6329.2721.4821.0621.0721.134.8FalseFalse24.38NAFalseFalseFalse32.7Healthcare63.3FalseFalseFalseFalseFalseFalse4.2False50.438.911.719False2164612.52821576.485880281.743090508.61914472.82False46.83.453.794.6855.65.84.94.85.211.211.278NA-0.8False,False;False,False;False,False[False, False, False]['2025-06-16', 59.6, '2026-03-30', 16.6]23.35Dec 2025:14/02/2026,Sep 2025:24/10/2025,Jun 2025:25/07/2025Sigachi Industries Limited-8.43.4Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0b40684-6451-4920-a5d5-e3fd9f148b30.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d704024a-de4f-45c7-8526-55d51642cf09.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/7afad9cd-c39e-4582-aa96-2bc03b5cefb9.pdf8.416.216.220.2NSE['DAILY', '2026-05-12', '2026-05-11']451242-0.0110.53-100.9716.1820.5121.0112.7615.17-100.1-1000.010.28-2.630.350.640.650.40.46-96.4-98.41.821.74117.21110.48128.25128.2139.42124.995.71104.136.1-15.928.554.886.8118.822.2723.7913.821.9615.68-28.3-79.5Dec 202513.515.540.2913.61
-10.6
-2.020-3.010.9952719.62Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder worldwide. The company manufactures pharmaceutical products, active and inactive ingredients, and nutritional and food ingredients. It exports its products. It serves pharmaceutical and nutraceutical, food and nutrition, cosmetic, and chemical industries. Sigachi Industries Limited was incorporated in 1989 and is based in Hyderabad, India. **Website:** [https://sigachi.com](https://sigachi.com)36.6962.011.31039.73.3301.59869.1211.591.8

Fundamental & Technical Parameters

Quarter
EPS
QoQ EPS
YoY EPS
Sales
QoQ Sales
YoY Sales
OPM
Dec 25
-2.48-6.0-0.88.457.5-43.3
-673.02
Sep 25
-2.34-46.229.57.86-18.5-38.9
-838.3
Jun 25
-1.614.946.39.64-64.5-42.7
-542.84
Mar 25
-1.8823.642.92782.464.2
-198.31
Market Cap
5399
% from 52W High
18.6
1 Month Returns(%)
16.9
3 Month Returns(%)
23.1

Company Info

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Website: https://www.sparc.life

Corporate Announcements

Press Release

30/04/2026

Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "SPARC Announces Sale of Priority Review Voucher for US $195 million".

Disclosure under SEBI Takeover Regulations

22/04/2026

Dilip S. Shanghvi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Certificate under SEBI (Depositories and Participants) Regulations, 2018

06/04/2026

Sun Pharma Advanced Research Company Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Resignation

03/04/2026

SPARC: Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Resignation of Ms. Shravanti Bhowmick as Head of Operations Management of the Company w.e.f. April 01, 2026.

Change in Management

27/03/2026

Sun Pharma Advanced Research Company Limited has informed the Exchange about Change in Management

AI Summary : Dec 2025

Company Overview

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company focused on research and development in technologically advanced and innovative therapeutic areas. The company has recently undergone a significant strategic reset, narrowing its focus to the high-potential fields of oncology and immunology after facing setbacks in neurodegeneration. This pivot is built on a strategy of executing well on a few prioritized, promising programs while building a robust preclinical pipeline around three core themes: targeted oncology, synthetic lethality, and dermatology autoimmune disorders. SPARC's approach is characterized by developing modular platforms, such as antibody-drug conjugates (ADCs) with interchangeable payloads, allowing for rapid expansion of its portfolio. The company also employs innovative development models, such as forming NewCos and partnerships, to advance assets while mitigating financial and clinical risk. With a restructured, leaner cost base and a clear focus on its lead assets—a novel topical agent for alopecia areata and a differentiated ADC for solid tumors—SPARC is positioning itself to deliver on key clinical milestones and create value through scientific innovation.

Official Website: https://sparc.life/presentations/

Financials

  • Cost Reduction Initiatives
  • The company has executed an aggressive cost optimization plan, resulting in annual fixed cost savings of approximately $10 million.
  • This was achieved by reducing headcount from over 400 in FY'24 to a projected 250 in the upcoming year.
  • The operational footprint has been consolidated by reducing the number of lab centers from four to two and significantly shrinking the US presence, which was primarily built for late-stage trials.
  • Operational Spend Management
  • Operational spending is being carefully controlled, projected to decrease from $31 million last year to $29 million this year.
  • This reduction is notable as it occurs while the company plans to scale up its clinical programs, demonstrating improved capital efficiency.
  • A key strategy for managing costs is increasing the use of India for early-stage, signal-seeking clinical studies, which offers a lower cost of failure.
  • Funding Status and Requirements
  • SPARC has been funding its development activities through promoter-backed debt, which amounted to over $45 million as of Q2 FY'26.
  • The company explicitly states it requires significant additional capital to deliver on its pipeline and future plans.
  • A funding plan is being finalized with the goal of extending the company's cash runway to FY'28. This process is expected to be completed in the first half of the current calendar year.
  • Potential Non-Dilutive Funding
  • SPARC has a significant near-term cash opportunity from a Pediatric Rare Disease Voucher (PRV).
  • A district court ruled that the agency's previous denial of the voucher was contrary to law. This decision is subject to a two-month appeal window expiring at the end of January.
  • The market value for these tradeable vouchers has been increasing, with transaction values reported to be north of $100 million. A positive outcome is described as potentially "transformational" for the company.

SPARC has significantly improved its cost structure and is managing operational spend effectively, but it carries substantial promoter debt and requires a new round of funding to execute its strategy, with a potential $100M+ cash infusion from a PRV on the horizon.

Business Uniqueness

  • Modular "Plug-and-Play" Platforms
  • SPARC's strategy in targeted oncology is to develop modular platforms. For instance, its MUC1 antibody can be combined with various payloads (MMAE, TOPO1, STING agonists), creating a multi-product franchise from a single validated targeting mechanism. This allows for efficient pipeline expansion.
  • Novel Scientific Approaches and Targets
  • MUC1-SEA Targeting: The company's lead ADC, SBO-154, targets a unique epitope on the MUC1 protein (the alpha-beta junction). This is designed to avoid the "peripheral sink" effect that may have limited previous MUC1-targeting drugs, potentially allowing for better tumor penetration and efficacy.
  • First-in-Class Immunology Pathway: The lead immunology asset, SCD-153, is a topical formulation of an itaconate analogue, an endogenous immunosuppressive metabolite. This represents a novel mechanism of action for treating autoimmune skin disorders like Alopecia Areata.
  • First-in-Class Oncology Targets: The preclinical pipeline includes a program targeting a chromatin remodeller involved in PARP inhibitor resistance, which is described as a potential first-in-class opportunity.
  • Alternative Development Structures (NewCo Model)
  • SPARC is utilizing a NewCo (New Company) structure to develop certain assets, such as SCO-155 for prostate cancer. By partnering with Tiller Therapeutics, SPARC retains significant equity upside while offloading the direct funding and development burden, thereby de-risking its portfolio.
  • Strategic Clinical Development in India
  • The company leverages the Indian clinical research environment to conduct early signal-seeking studies at a significantly lower cost. This allows for efficient validation of new compounds before committing to more expensive global trials.

SPARC's unique approach is defined by its modular drug development platforms, its focus on novel and potentially first-in-class scientific targets, and its use of innovative business structures to advance its pipeline in a capital-efficient manner.

Industry Situation and Outlook

  • Targeted Oncology (ADCs and RLTs)
  • The Antibody-Drug Conjugate (ADC) field is experiencing a major resurgence, described as one of the "richest pipeline segments in oncology," validated by the commercial success of products like Enhertu and Trodelvy. This strong industry tailwind supports SPARC's strategic focus.
  • Radioligand therapies (RLTs), exemplified by Novartis' PLUVICTO, are gaining traction, validating the use of small molecule ligands for targeted delivery, which aligns with SPARC's approach for assets like SCO-155.
  • Immuno-Oncology (T-Cell Engagers)
  • T-cell engagers (TCEs) are a mature and validated class in hematological cancers, but their application in solid tumors has been limited by safety issues like cytokine release syndrome (CRS). The industry is now focused on developing next-generation constructs with better safety profiles, which is precisely the area SPARC is targeting with its MUC1-SEA Albufusion TCE.
  • Dermatology Autoimmune Disorders
  • The market for conditions like Alopecia Areata and Vitiligo has significant unmet needs. Current standards of care, including corticosteroids and JAK inhibitors, have long-term safety concerns or middling efficacy, creating a clear opportunity for novel, safer topical alternatives like SPARC's SCD-153.
  • Chronic Myeloid Leukemia (CML)
  • The CML treatment landscape is highly competitive and rapidly evolving. The market has seen increased generalization of TKIs and the introduction of second and third-generation products in earlier lines of therapy. The emergence of powerful new drugs like asciminib makes the development pathway for new entrants like SPARC's vodobatinib "challenging."

The company is strategically positioned in high-growth, innovative sectors like ADCs and next-generation immuno-oncology, while the opportunity in dermatology is driven by unmet needs; however, it faces a highly competitive and challenging environment in the mature CML market.

Growth

  • Prioritized Clinical Programs as Key Drivers
  • SCD-153 (Alopecia Areata): This program is a near-term value driver. With Phase 1B ongoing, preliminary safety and efficacy data is expected by Q4 2026. A positive readout would trigger a larger global Phase 2 trial and validate the underlying itaconate platform.
  • SBO-154 (MUC1 ADC): As the lead oncology asset, this program's progression is critical. The Phase 1 dose escalation is underway, with the maximum tolerated dose expected by Q3 2026. Success here would de-risk the entire MUC1 platform and allow for expansion into specific tumor types.
  • Pipeline Expansion and Platform Validation
  • Indication Expansion for SCD-153: The company is actively exploring SCD-153 for Vitiligo, another dermatological condition with a similar immune pathogenesis. Positive preclinical data could open up a second major market for this asset.
  • Leveraging the MUC1 Platform: Once the MUC1 targeting hypothesis is validated with SBO-154, SPARC plans to rapidly advance other ADCs using the same antibody but with different payloads (e.g., a TOPO1 inhibitor, a STING agonist), creating a pipeline within a pipeline.
  • Advancing Preclinical Assets: Growth will be fueled by transitioning high-potential preclinical assets into the clinic. Key programs to watch are the radio/chemosensitizer from the synthetic lethality platform and the second-generation MUC1 T-cell engager.
  • Value Creation through Partnerships
  • The NewCo model with Tiller Therapeutics for SCO-155 serves as a template. Successful progression of this asset to IND and beyond will demonstrate the viability of this model, which could then be applied to other programs, like vodobatinib, to unlock value without direct investment from SPARC.

Growth is primarily contingent on the successful clinical execution of its two lead assets, SCD-153 and SBO-154, which will in turn validate the company's core platforms and enable the advancement of a deep, synergistic pipeline.

Opportunities

  • Near-Term Capital Injection via PRV
  • A favorable final outcome on the Pediatric Rare Disease Voucher (PRV) represents a transformative, non-dilutive funding opportunity. An encashment north of $100 million would significantly strengthen the balance sheet and allow the company to more aggressively fund its pipeline.
  • Commercialization of Out-Licensed Asset (PDP-716)
  • Despite manufacturing challenges, the resubmission of the NDA for PDP-716 by partner Ocuvex Therapeutics presents a potential near-term revenue stream through milestones and royalties if regulatory approval is achieved.
  • Unlocking Value in Stalled Assets
  • The company is exploring alternative structures, such as partnerships or NewCos, for its CML asset, vodobatinib. This presents an opportunity to monetize an asset that is too costly and challenging for SPARC to develop on its own in the current competitive landscape.
  • First-in-Class Potential in Synthetic Lethality
  • The preclinical programs targeting DNA damage repair pathways offer significant upside. The program targeting a chromatin remodeller for PARP inhibitor resistance is highlighted as a potential first-in-class opportunity, which, if successful, could command significant value.
  • Addressing Unmet Needs in Dermatology
  • SCD-153 is positioned to capture a significant market opportunity in autoimmune skin disorders by offering a potentially safer and effective topical alternative to systemic therapies or agents with known safety liabilities. The planned expansion into vitiligo further enhances this opportunity.

SPARC has a major near-term opportunity to secure over $100 million in non-dilutive funding, complemented by potential revenue from a partnered asset and long-term value creation from its first-in-class preclinical programs.

Future Plans

  • Near-Term (Next 12 Months)
  • Funding: Complete the ongoing funding plan in the first half of 2026 to extend the cash runway to FY'28.
  • Vodobatinib: Make a final decision on the future pathway for the vodobatinib program "fairly soon."
  • SCD-153 (Alopecia Areata): Complete enrollment for the Phase 1B study in Q3 2026 and report top-line results in Q4 2026.
  • SBO-154 (MUC1 ADC): Identify the maximum tolerated dose (MTD) by the end of Q3 2026 and initiate dose expansion cohorts by the end of 2026.
  • Preclinical to Clinical Transition: Advance the radio/chemosensitizer compound into the clinic before the end of the next financial year.
  • Medium-Term (12-24 Months)
  • SCD-153: Initiate a global Phase 2 clinical study in Alopecia Areata in Q2 2027 and potentially initiate a clinical study in Vitiligo.
  • SBO-154: Obtain early clinical proof-of-concept data from the expansion cohorts by the second half of 2027.
  • Biologics Pipeline: Advance additional assets from the biologics portfolio (e.g., MUC1-TCE, bispecific ADCs) towards IND-enabling studies.
  • SCO-155: Support partner Tiller Therapeutics in advancing SCO-155 towards an IND filing.

The company's future plans are focused on executing critical clinical milestones for its two lead assets over the next 12-18 months, which will serve as the primary value catalysts while advancing its next wave of preclinical assets into the clinic.

Competition Overview

  • Chronic Myeloid Leukemia (CML)
  • The field is crowded with established TKIs. The primary competitive threat mentioned is asciminib, a newer allosteric inhibitor that is becoming a "significant option for CML patients across the spectrum," raising the bar for new therapies like vodobatinib.
  • Dermatology Autoimmune (Alopecia Areata & Vitiligo)
  • The current standard of care consists of corticosteroids, calcineurin inhibitors, and, more recently, oral and topical JAK inhibitors. SPARC's SCD-153 will compete by aiming to offer a better long-term safety profile and comparable or synergistic efficacy.
  • Synthetic Lethality
  • SPARC is competing with multiple large pharmaceutical companies in this space. For its lead radio/chemosensitizer asset, the company notes that its compound has outperformed a "leading second-generation compound" from a competitor that is currently in early-stage clinical trials.

SPARC faces intense competition from established and emerging therapies in CML and dermatology, but believes its novel mechanisms and preclinical data suggest a potential for differentiation.

Risks

  • Funding and Financial Risk
  • The company explicitly states its need for "significant additional resources" and is dependent on the successful completion of a new funding round. Failure to secure this capital would severely impede its ability to execute its clinical and preclinical plans. The existing promoter-backed debt of over $45 million also represents a financial liability.
  • Clinical Development Risk
  • SPARC's portfolio is early-stage, with its key assets yet to achieve clinical proof-of-concept. The CEO directly references past failures with the PROSEEK and Vibozilimod trials as a reminder of the inherent risks in drug development and advises investors to take a "probability-adjusted view."
  • Regulatory and Manufacturing Risk
  • The case of PDP-716 highlights tangible risks. The program was delayed by a Complete Response Letter due to issues at a third-party API vendor and now faces further hurdles related to compliance issues at the finished product manufacturing site. These external dependencies can cause significant delays and jeopardize commercialization.
  • Competitive Landscape Risk
  • The rapid evolution of the CML market demonstrates how quickly a competitive landscape can shift, making a once-promising asset like vodobatinib a "challenging" proposition. Similar competitive pressures could emerge in the company's other focus areas.
  • Partnership and Dependency Risk
  • The success of the SCO-155 program is dependent on the ability of its partner, Tiller Therapeutics, to raise capital and successfully execute the development plan. SPARC has limited direct control over this process.

The primary risks are financial dependency on a forthcoming funding round and the inherent clinical trial risk of an early-stage pipeline, compounded by potential manufacturing and competitive pressures.

Other Key Business Updates

  • Completion of Strategic Reset
  • The company has successfully completed its strategic pivot away from disparate projects and neurodegeneration to a focused portfolio in oncology and immunology, built around three cohesive themes.
  • Positive Litigation Outcome for PRV
  • SPARC received a favorable ruling from the District Court of Columbia regarding its Pediatric Rare Disease Voucher (PRV), stating the agency's denial was "contrary to law." This significantly increases the probability of receiving the voucher, pending a potential appeal.
  • Progress with SCO-155 NewCo
  • The partnership with Tiller Therapeutics for the development of SCO-155 is progressing well. IND-enabling toxicology studies are nearly complete, pre-IND consultation with the FDA has been conducted, and Tiller is in the process of raising external seed capital.
  • Partner Change for PDP-716
  • The commercialization rights for PDP-716, a once-a-day formulation of Brimonidine, are now held by Ocuvex Therapeutics following its acquisition of the original licensee, Visiox Pharma.

Disclaimer: This stock summary is generated by AI. ChartsMaze does not guarantee its accuracy, completeness, or timeliness. The data may be outdated and may not reflect real-time events or news. Please verify the information independently before making any investment decisions. For more details, check our Terms & Conditions.